Flamel Technologies Announces Projected Release Date of Fourth Quarter and Year-End 2011 Results; Additional Releases; Confer...
14 3월 2012 - 5:15AM
Marketwired
Flamel Technologies (NASDAQ: FLML) expects to
release its financial results for the fourth quarter and the fiscal
year 2011, as well as additional releases, on Wednesday, March
14th, after the market close. A conference call to discuss these
results as well as additional releases has been scheduled for
Thursday, March 15th, at 8:30 AM (Eastern Daylight Time). A
question and answer period is scheduled to follow management's
prepared remarks.
To participate in the conference call, investors are invited to
dial 1-888-256-9132. The conference ID number is 4062934. The
conference call webcast may be accessed at www.flamel.com.
About Flamel Technologies. Flamel
Technologies SA (NASDAQ: FLML) is a leading drug delivery company
focused on the goal of developing safer, more efficacious
formulations of drugs that address unmet medical needs. Its product
development pipeline includes biological and chemical drugs
formulated with the Medusa® and Micropump® proprietary platforms.
Several Medusa-based products are at various clinical stages of
development; Medusa's lead internal product candidate IFN-alpha XL
(long-acting interferon alpha-2b) is being evaluated in a Phase 2a
trial in HCV patients. The Company has developed approved products
and manufactures Micropump-based microparticles under FDA-audited
GMP guidelines. Flamel Technologies has collaborations with a
number of leading pharmaceutical and biotechnology companies,
including GlaxoSmithKline plc (Coreg CR®, carvedilol phosphate) and
Merck Serono S.A. (long acting interferon beta-1a). Additional
information can be found at www.flamel.com.
This document contains a number of matters that constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. This release reflects the
current view of management with respect to future events and is
subject to risks and uncertainties that could cause actual results
to differ materially from those contemplated in such
forward-looking statements. These risks include risks that products
in the development stage may not achieve scientific objectives or
milestones or meet stringent regulatory requirements, uncertainties
regarding market acceptance of products in development, the impact
of competitive products and pricing, and the risks associated with
Flamel's reliance on outside parties and key strategic alliances.
These and other risks are described more fully in Flamel's Annual
Report on the Securities and Exchange Commission Form 20-F for the
year ended December 31, 2010.
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024